LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "ccnu" as a keyword



Photo from wikipedia

Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models12

Sign Up to like & get
recommendations! Published in 2017 at "Translational Oncology"

DOI: 10.1016/j.tranon.2017.06.003

Abstract: Resistance to chemotherapy remains a major challenge in the treatment of human glioblastoma (GBM). Glycogen synthase kinase-3β (GSK-3β), a positive regulator of NF-κB–mediated survival and chemoresistance of cancer cells, has been identified as a potential… read more here.

Keywords: combination; inhibitor ing; treatment; ccnu ... See more keywords
Photo from wikipedia

Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden.

Sign Up to like & get
recommendations! Published in 2019 at "Neuro-oncology practice"

DOI: 10.1093/nop/npy021

Abstract: Background Since its approval for use in recurrent glioblastoma (GBM), the survival benefit of bevacizumab (Bev) remains to be demonstrated. To address this issue, we retrospectively examined survival from first recurrence in patients treated with… read more here.

Keywords: first recurrence; patients large; bev; tumor ... See more keywords
Photo by jaredmurray from unsplash

Risk factors associated with the onset of lomustine-induced neutropenia in tumour-bearing dogs.

Sign Up to like & get
recommendations! Published in 2022 at "Veterinary and comparative oncology"

DOI: 10.1111/vco.12809

Abstract: Lomustine (CCNU) is an oral alkylating agent in the nitrosourea subclass that can cause myelosuppression, with neutropenia being the main dose-limiting toxicity. The aim of this study was to define the frequency of neutropenic events… read more here.

Keywords: lomustine; ccnu; bearing dogs; risk ... See more keywords
Photo from wikipedia

Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell–dependent regression of glioblastoma

Sign Up to like & get
recommendations! Published in 2023 at "Science Translational Medicine"

DOI: 10.1126/scitranslmed.adf2281

Abstract: Glioblastoma is the most aggressive primary brain tumor with an unmet need for more effective therapies. Here, we investigated combination therapies based on L19TNF, an antibody-cytokine fusion protein based on tumor necrosis factor that selectively… read more here.

Keywords: ccnu; glioblastoma; combination; tumor necrosis ... See more keywords